THYMUS 3

POM TR. 033 318 411
(Distribution Permit Number from Board of Drug and Food Control the Republic of Indonesia)

Pharmacology

Thymus gland is the only clearly individualized primary lymphoid organ in mammals It plays a key role in determining the differentiation of T lymphocytes by producing thymic proteins (e.g. thymosin and thymopoietin) from thymic epithelial cells to enhance T lymphocytes function. Thymus gland is an essential organ of the immune system that is able to activate many immune responses, especially the cellular immune response.⁽¹⁾

 is a freeze dried young goat thymus glands extract that is used as complementary therapy against cancer and viral infections. These are the thymic hormones in :

1. Thymostimulin, M.W. 12,000 kDa
2. Thymopoietin, M.W. 5,562 kDa
3. Tβ4 (Thymosin β4), M.W. 4,963 kDa
4. TFX (Thymic Factor X), M.W. 4,200 kDa
5. THF (Thymic Humoral Factor), M.W. 3,200 kDa
6. Tα1 (Thymosin α1), M.W. 3,108 kDa
7. FTS (Factor Thymic Series), M.W. 847 kDa

* for detailed information, please see product application

Composition

• Thymus gland extract60mg
• Filler up to340mg

Indication

• To enhance the immune system

Contraindication

• Hypersensitivity to thymus gland extract
• Patient under immunosuppressive treatment

Precaution

• Stop using when undesirable symptoms occurred. Please consult your doctor

Adverse Reaction

• No report

Dose

• 1-3 capsules, at the same time or apart dose

Administration

• ½ hour before or 1 hour after meals

Storage

• Keep in dry and cool place

Packaging

Box of bottle, 30 capsules @ 60 mg thymus gland extract and filler up to 400 mg

Description : Each capsule contains 60 mg of protein extract from kid goat thymus gland

as Complementary Therapy in Cancer

Lymphocyte T is a component of cellular immune system that matures in the thymus gland. The thymus gland contains thymic hormones that control the maturation, development and antigen commitment of T lymphocytes.

Only mammalians have the thymus gland that grows until puberty; then it starts to degrade, resulting in the disturbance of T lymphocyte maturation and immunosuppression in adults. Cellular immune response depletion is associated with poor prognosis in cancer because it influences cancer growth and metastasis.⁽¹⁾

Based on this reason, the use of thymus gland extract as a complementary therapy to increase cellular immune system response has beneficial effect for cancer patients.⁽²⁾  is thymus gland extract that stimulates T lymphocyte maturation and develops cellular immune response activation against cancer cells.

Fig. 11. Bioactive Substances in 

Studies showed that a thymic hormone known as Thymosin α1 (Tα1) was able to inhibit proliferation and stimulate apoptosis of human leukemic cell lines (HL-60, K562 and K562/ADM).⁽³⁾ Tα1 administration concomitant with Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC) patients resulted in higher survival rate compared to patients who were only treated with TACE.⁽⁴⁾ The other thymic hormone, thymostimulin (TP1), is able to neutralize p15E-like factor secreted by head and neck squamous cell carcinoma. P15E-like factor is an immunosuppressive factor that inhibits monocyte chemotactic capability.⁽⁵⁾

as a Complementary Therapy in Hepatitis B and C

Viral Hepatitis B and C (HBV and HCV) generally proceed to chronic hepatitis, fibrosis, cirrhosis and even liver cancer (hepatocellular carcinoma/HCC). Until today, standard therapies for viral hepatitis infection are Interferon-α (IFN-α) and nucleoside analog (anti-viral), but both of them only reach low rates of efficacy. In addition, the long term use of analog nucleoside can exert resistance because HBV or HCV are known to have high mutation rate.

Tα1 is a thymic hormone that stimulates T lymphocyte maturation and activation. Lymphocyte T-mediated immune response is important in viral hepatitis elimination. A clinical study shows that Tα1 treatment in chronic hepatitis B patient for 6 months results in sustained response until 12 months follow up compared to patients treated with IFN-α. Reduction of HBeAg and HBV DNA in Tα1-treated patients at the end of therapy (6 months) is lower than IFN-α, but at the end of follow up (12 months) reduction of HBeAg and HBV DNA in Tα1-treated patients is higher than IFNα. Delayed response exerted by Tα1 may be due to its activity and is not likely a direct antiviral effect which competes with viral nucleoside. However, it stimulates host cellular immune response in viral hepatitis elimination through noncytolytic viral clearance mechanism.⁽⁶⁾

Fig. 12. Inhibition of Viral Hepatitis Replication by Thymus Extract

 Download PDF